Protease-based subunit vaccine in mice boosts BCG protection against mycobacterium tuberculosis
Nenhuma Miniatura disponível
Data
2022
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The significant number of people with latent and active tuberculosis infection requires
further efforts to develop new vaccines or improve the Bacillus Calmette-Guérin (BCG), which is
the only approved vaccine against this disease. In this study, we developed a recombinant fusion
protein (PEPf) containing high-density immunodominant epitope sequences from Rv0125, Rv2467,
and Rv2672 Mycobacterium tuberculosis (Mtb) proteases that proved immunogenic and used it to
develop a recombinant BCG vaccine expressing the fusion protein. After challenging using Mtb,
a specific immune response was recalled, resulting in a reduced lung bacterial load with similar
protective capabilities to BCG. Thus BCG PEPf failed to increase the protection conferred by BCG.
The PEPf was combined with Advax4 adjuvant and tested as a subunit vaccine using a prime-boost
strategy. PEPf + Advax4 significantly improved protection after Mtb challenge, with a reduction in
bacterial load in the lungs. Our results confirm that Mtb proteases can be used to develop vaccines
against tuberculosis and that the use of the recombinant PEPf subunit protein following a prime-boost
regimen is a promising strategy to improve BCG immunity
Descrição
Palavras-chave
Tuberculosis, Subunit vaccine, PepN, PepA/Mtb32a, Msh1, Recombinant BCG, Adjuvant, Advax4
Citação
JUNQUEIRA-KIPNIS, Ana Paula et al. Protease-based subunit vaccine in mice boosts BCG protection against mycobacterium tuberculosis. Vaccines, Basel., v. 10, n. 2, e306, 2022. DOI: 10.3390/vaccines1002030. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35214766/. Acesso em: 19 ago. 2024.